Get the Stockscreener App
2.29
1.72%
-0.04
Lantern Pharma Inc stock is traded at $2.29, with a volume of 141.14K.
It is down -1.72% in the last 24 hours and down -4.18% over the past month.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
See More
Previous Close:
$2.33
Open:
$2.35
24h Volume:
141.14K
Relative Volume:
0.28
Market Cap:
$25.77M
Revenue:
-
Net Income/Loss:
$-17.12M
P/E Ratio:
-1.4587
EPS:
-1.5699
Net Cash Flow:
$-15.68M
1W Performance:
+18.04%
1M Performance:
-4.18%
6M Performance:
-48.19%
1Y Performance:
-34.94%
1-Day Range:
$2.22
$2.3837
1-Week Range:
$1.85
$2.3837
52-Week Range:
$1.11
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.29 | 26.22M | 0 | -17.12M | -15.68M | -1.5699 |
VRTX
Vertex Pharmaceuticals Inc
|
440.44 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.20 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.24 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.23 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.67 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma (LTRN) Launches AI Platform for Cancer Research - GuruFocus
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Can - pharmiweb.com
Lantern Pharma launches AI platform for rare cancer research - Investing.com
Lantern Pharma Inc. Launches withZeta.ai, the Worlds First Multi Agentic AU Co Scientist for Rare Cancer Drug Discovery and Development - marketscreener.com
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify - MSN
Lantern Pharma Showcases withZeta.ai Platform for Rare Cancers - TipRanks
Lantern Pharma showcases withZeta.ai platform, outlines commercial architecture and near-term revenue strategy - TradingView — Track All Markets
Lantern Pharma (NASDAQ: LTRN) showcases withZeta.ai rare cancer AI - Stock Titan
LTRN Technical Analysis & Stock Price Forecast - Intellectia AI
Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - Stock Titan
Why is Lantern Pharma stock soaring Monday? - MSN
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026 - Yahoo Finance
Lantern Pharma Engages New to The Street for National Media Coverage Featuring Television, Press, Earned Media and Non-Deal Investor Focused Roadshows - Foster's Daily Democrat
Fed Meeting: Whats the outlook for Lantern Pharma Incs sectorWeekly Market Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Progress Index
LTRN PE Ratio & Valuation, Is LTRN Overvalued - Intellectia AI
LTRN stock gains 18% pre-market: FDA greenlights first pediatric cancer trial for AI-driven drug - MSN
Lantern Pharma’s Dramatic Slide Reflects Key Strategic Uncertainties - timothysykes.com
Lantern Pharma Reports 2025 Financial Results - National Today
Lantern Pharma Inc. Announces Proposed Public Offering of Common Stock - Issuewire
Lantern Pharma Q4 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens - Investing.com Australia
Lantern Pharma Announces Termination of Proposed Public Offering - Issuewire
Lantern Pharma Q4 2025 slides: EPS beats as cash runway tightens By Investing.com - Investing.com South Africa
Lantern Pharma Inc. announces plan for best-efforts public offering of common stock. - bitget.com
Lantern Pharma Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Lantern Pharma Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-03-30 - Seeking Alpha
Lantern Pharma (LTRN) Achieves Key Milestones in Oncology Develo - GuruFocus
Lantern Pharma Reports 2025 Results and Pipeline Progress - TipRanks
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - 01net
Lantern Pharma (LTRN) Dismisses False CEO Resignation Rumor - GuruFocus
Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk - Stock Titan
Lantern Pharma (NASDAQ: LTRN) seeks equity via best‑efforts placement with warrants - Stock Titan
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps By Investing.com - Investing.com South Africa
Earnings call transcript: Lantern Pharma Q4 2025 sees EPS improvement, stock jumps - Investing.com Australia
Lantern Pharma (NASDAQ: LTRN) trims 2025 loss as cash runway shrinks into 2026 - Stock Titan
Q4 2025 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma : Fourth Quarter 2025 Financial Results Conference Call - marketscreener.com
Lantern Pharma : Fourth Quarter 2025 Presentation - marketscreener.com
Dallas company secures FDA approval for pediatric cancer drug trial - The Business Journals
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - marketscreener.com
Lantern Pharma (LTRN) price target increased by 25.00% to 25.50 - MSN
Lantern Pharma Shares Rise; What's The Buzz? - RTTNews
Lantern Pharma Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aug Volume: What are Lantern Pharma Incs recent SEC filings showingQuarterly Performance Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
2.21%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):